References
  1. Jafri SM, Gordon SC. Epidemiology of Hepatitis C. Clinical Liver Disease 2018; 12:140-142.
  2. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123(6):2082-2099.
  3. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol 2017; 2:161-176.
  4. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
  5. Bian DD, Zhou HY, Liu S, et al. Current treatment status and barriers for patients with chronic HCV infection in mainland China: a national multicenter cross-sectional survey in 56 hospitals. Medicine 2017; 96(34):e7885.
  6. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. The guideline of prevention and treatment for hepatitis C: 2015 updated version. Clin J Viral Dis 2015; 5(6):425-447.
  7. Zhao N, Xie R, Zhao X, et al. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers. Clin Drug Investig. 2019; 39(7):671-681.
  8. Zhang H, Zhu X, Li Q, et al. Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus. J Pharm Pharmacol 2018; 70(7):855-864.
  9. Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol 2017; 13(4):483-490.
  10. German P, Mathias A, Brainard D, et al. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. Clin Pharmacokinet 2016; 55(11):1337-1351.
  11. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28(5):481-504.
  12. Cockcroft DW, Gault MH. Prediction of Creatinine Clearance from Serum Creatinine. Nephron 1976; 16:31-41.
  13. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11(3):558-569.
  14. Carver PL, Fleisher D, Zhou SY, et al. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res 1999; 16(5):718-724.
Figure 1. The chemical structure of yimitasvir.
Figure 2. Goodness-of-fit plots of final population pharmacokinetics model. (A) Observed drug concentration (DV) versus individual prediction (IPRED); (B) DV versus population prediction (PRED); (C) conditional weighted residual (CWRES) versus PRED; (D) CWRES versus time after dose (TAD). The black line is the line of unity or the zero reference line, and the red line is the result of locally weighted scatterplot smoothing (loess).
Figure 3. Prediction-corrected visual predictive check (pcVPC) plot stratified by study. Black circles are observed yimitasvir concentrations, red solid lines represent the median of predicted concentrations, and grey dashed lines represent the 5th and 95th percentiles of predicted concentrations.
Figure 4. Sensitive plot comparing the effect of covariates on yimitasvir steady state exposure. (A) AUCss; (B) Ctrough,ss; (C) Cmax,ss. A typical subject is a healthy male volunteer with ALT value of 31.6 IU l-1 taking yimitasvir under fasted state more than 10 h. The black bar represents the 5th to 95th percentile of the exposure calculated using empirical Bayes estimates of the population after administration of yimitasvir 100 mg once daily for 12 consecutive weeks. Continuous covariates were evaluated at the 5th to 95th percentile of the population.